FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vaccines (Basel) / Determining Equine Influenza Virus Vaccine Efficacy-The Spec...
Vaccines2020; 8(3); 501; doi: 10.3390/vaccines8030501

Determining Equine Influenza Virus Vaccine Efficacy-The Specific Contribution of Strain Versus Other Vaccine Attributes.

Abstract: Vaccination is an effective tool to limit equine influenza virus (EIV H3N8) infection, a contagious respiratory disease with potentially huge economic impact. The study assessed the effects of antigenic change on vaccine efficacy and the need for strain update. Horses were vaccinated (V1 and V2) with an ISCOMatrix-adjuvanted, whole inactivated virus vaccine (Equilis Prequenza, group 2, FC1 and European strains) or a carbomer-adjuvanted, modified vector vaccine (ProteqFlu, group 3, FC1 and FC2 HA genes). Serology (SRH, HI, VN), clinical signs and viral shedding were assessed in comparison to unvaccinated control horses. The hypothesis was that group 2 (no FC2 vaccine strain) would be less well protected than group 3 following experimental infection with a recent FC2 field strain (A/equi-2/Wexford/14) 4.5 months after vaccination. All vaccinated horses had antibody titres to FC1 and FC2. After challenge, serology increased more markedly in group 3 than in group 2. Vaccinated horses had significantly lower total clinical scores and viral shedding. Unexpectedly, viral RNA shedding was significantly lower in group 2 than in group 3. Vaccination induced protective antibody titres to FC1 and FC2 and reduced clinical signs and viral shedding. The two tested vaccines provided equivalent protection against a recent FC2 EIV field strain.
Get Full Text
Publication Date: 2020-09-03 PubMed ID: 32899189PubMed Central: PMC7564743DOI: 10.3390/vaccines8030501Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article discusses the impact of different strains and attributes of equine influenza virus (EIV H3N8) vaccines on their efficacy. The study found that both a whole inactivated virus vaccine and a modified vector vaccine were equally effective against a recent field strain of the virus.

Objective and Hypothesis

  • The primary objective of the study was to investigate the implications of antigenic alterations on the efficacy of vaccines against equine influenza virus (EIV H3N8), a highly contagious respiratory disease in horses that can have significant economic consequences.
  • The researchers hypothesized that a vaccine group excluding the FC2 strain (group 2) would experience lesser protection than a group including it (group 3), after infection with a recent FC2 field strain.

Methodology

  • Horses were vaccinated with either an ISCOMatrix-adjuvanted, whole inactivated virus vaccine (Equilis Prequenza), featuring FC1 and European strains, or a carbomer-adjuvanted, modified vector vaccine (ProteqFlu), containing FC1 and FC2 HA genes.
  • Serology, clinical indications, and viral shedding were examined and compared to those in a control group of non-vaccinated horses.
  • The horses’ infections were induced with a recent FC2 field strain 4.5 months post-vaccination.

Findings

  • Results showed all vaccinated horses, regardless of vaccine group, displayed antibody titres to both FC1 and FC2.
  • After the induced infection, serology levels increased more notably in the group vaccinated with the FC1 and FC2 HA genes (group 3) than those vaccinated with the FC1 and European strains (group 2).
  • However, both groups of vaccinated horses demonstrated notably lower total clinical scores and viral shedding compared to the control.
  • In an unexpected finding, viral RNA shedding was found to be significantly lower in group 2 than in group 3.

Conclusion

  • The research concludes that both the whole inactivated virus vaccine and the modified vector vaccine were able to elicit protective antibody titres to FC1 and FC2, leading to reduced clinical signs and viral shedding in horses.
  • The two tested vaccines provided comparable protection against a recent FC2 EIV field strain, indicating that the efficacy of different EIV vaccines is not solely dependent on the specific strain but also involves other vaccine attributes.

Cite This Article

APA
Reemers S, Sonnemans D, Horspool L, van Bommel S, Cao Q, van de Zande S. (2020). Determining Equine Influenza Virus Vaccine Efficacy-The Specific Contribution of Strain Versus Other Vaccine Attributes. Vaccines (Basel), 8(3), 501. https://doi.org/10.3390/vaccines8030501

Publication

Vaccines
ISSN: 2076-393X
NlmUniqueID: 101629355
Country: Switzerland
Language: English
Volume: 8
Issue: 3
PII: 501

Researcher Affiliations

Reemers, Sylvia
  • MSD Animal Health, Wim de Körverstraat 35, 5831 AN Boxmeer, The Netherlands.
Sonnemans, Denny
  • MSD Animal Health, Wim de Körverstraat 35, 5831 AN Boxmeer, The Netherlands.
Horspool, Linda
  • MSD Animal Health, Wim de Körverstraat 35, 5831 AN Boxmeer, The Netherlands.
van Bommel, Sander
  • MSD Animal Health, Wim de Körverstraat 35, 5831 AN Boxmeer, The Netherlands.
Cao, Qi
  • MSD Animal Health, Wim de Körverstraat 35, 5831 AN Boxmeer, The Netherlands.
van de Zande, Saskia
  • MSD Animal Health, Wim de Körverstraat 35, 5831 AN Boxmeer, The Netherlands.

Conflict of Interest Statement

All authors are employed by the study sponsor (MSD Animal Health). The authors were not involved in performance of the animal phase of the study nor in collection of samples, clinical data, SRH data and qPCR data. Vaccines were masked during the study, laboratory analysis of the samples, and data analysis.

References

This article includes 45 references
  1. Landolt G, Townsend H.G, Lunn D.P. Equine influenza infection. In: Sellon D.C., Long M.T., editors. Equine Infectious Diseases. 2nd ed. Saunders Elsevier; Amsterdam, The Netherland: 2013. pp. 141–151.
  2. The World Organisation for Animal Health (OIE) Information on Aquatic and Terrestrial Animal Diseases, Equine Influenza. [(accessed on 1 August 2019)]; Available online: https://www.oie.int/en/animal-health-in-the-world/animal-diseases/equine-influenza.
  3. Webster WR. Overview of the 2007 Australian outbreak of equine influenza.. Aust Vet J 2011 Jul;89 Suppl 1:3-4.
    doi: 10.1111/j.1751-0813.2011.00721.xpubmed: 21711267google scholar: lookup
  4. Paillot R. A Systematic Review of Recent Advances in Equine Influenza Vaccination.. Vaccines (Basel) 2014 Nov 14;2(4):797-831.
    doi: 10.3390/vaccines2040797pmc: PMC4494246pubmed: 26344892google scholar: lookup
  5. Paillot R, Prowse L, Montesso F, Stewart B, Jordon L, Newton JR, Gilkerson JR. Duration of equine influenza virus shedding and infectivity in immunised horses after experimental infection with EIV A/eq2/Richmond/1/07.. Vet Microbiol 2013 Sep 27;166(1-2):22-34.
    doi: 10.1016/j.vetmic.2013.04.027pubmed: 23769636google scholar: lookup
  6. Gildea S, Arkins S, Cullinane A. Management and environmental factors involved in equine influenza outbreaks in Ireland 2007-2010.. Equine Vet J 2011 Sep;43(5):608-17.
    doi: 10.1111/j.2042-3306.2010.00333.xpubmed: 21496094google scholar: lookup
  7. Gildea S, Arkins S, Walsh C, Cullinane A. A comparison of antibody responses to commercial equine influenza vaccines following primary vaccination of Thoroughbred weanlings--a randomised blind study.. Vaccine 2011 Nov 15;29(49):9214-23.
    doi: 10.1016/j.vaccine.2011.09.101pubmed: 21983355google scholar: lookup
  8. Cullinane A, Newton JR. Equine influenza--a global perspective.. Vet Microbiol 2013 Nov 29;167(1-2):205-14.
    doi: 10.1016/j.vetmic.2013.03.029pubmed: 23680107google scholar: lookup
  9. Daly JM, MacRae S, Newton JR, Wattrang E, Elton DM. Equine influenza: a review of an unpredictable virus.. Vet J 2011 Jul;189(1):7-14.
    doi: 10.1016/j.tvjl.2010.06.026pubmed: 20685140google scholar: lookup
  10. Wattrang E, Jessett DM, Yates P, Fuxler L, Hannant D. Experimental infection of ponies with equine influenza A2 (H3N8) virus strains of different pathogenicity elicits varying interferon and interleukin-6 responses.. Viral Immunol 2003;16(1):57-67.
    doi: 10.1089/088282403763635456pubmed: 12725689google scholar: lookup
  11. Gildea S, Arkins S, Walsh C, Cullinane A. A comparison of antibody responses to commercial equine influenza vaccines following annual booster vaccination of National Hunt horses - a randomised blind study.. Vaccine 2011 May 17;29(22):3917-22.
    doi: 10.1016/j.vaccine.2011.03.003pubmed: 21419776google scholar: lookup
  12. Paillot R, Prowse L, Montesso F, Huang CM, Barnes H, Escala J. Whole inactivated equine influenza vaccine: Efficacy against a representative clade 2 equine influenza virus, IFNgamma synthesis and duration of humoral immunity.. Vet Microbiol 2013 Mar 23;162(2-4):396-407.
    doi: 10.1016/j.vetmic.2012.10.019pubmed: 23146168google scholar: lookup
  13. Wood JL, Mumford JA, Mair TS, Slater J. Boosting in equine influenza vaccination schedules: timing and time for a re-evaluation of requirements of national and international authorities.. Vet J 2007 Nov;174(3):449-50.
    doi: 10.1016/j.tvjl.2007.06.012pubmed: 17702620google scholar: lookup
  14. Murcia PR, Baillie GJ, Stack JC, Jervis C, Elton D, Mumford JA, Daly J, Kellam P, Grenfell BT, Holmes EC, Wood JL. Evolution of equine influenza virus in vaccinated horses.. J Virol 2013 Apr;87(8):4768-71.
    doi: 10.1128/JVI.03379-12pmc: PMC3624384pubmed: 23388708google scholar: lookup
  15. . Conclusions and Recommendations. OIE Expert Surveillance Panel on Equine Influenza Vaccine Composition, OIE Headquarters, 16 April 2020. [(accessed on 1 June 2020)]; Available online: https://www.oie.int/scientific-expertise/specific-information-and-recommendati.;ons/equine-influenza/.
  16. Hinshaw VS, Naeve CW, Webster RG, Douglas A, Skehel JJ, Bryans J. Analysis of antigenic variation in equine 2 influenza A viruses.. Bull World Health Organ 1983;61(1):153-8.
    pmc: PMC2536062pubmed: 6601538
  17. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses.. Microbiol Rev 1992 Mar;56(1):152-79.
    doi: 10.1128/MMBR.56.1.152-179.1992pmc: PMC372859pubmed: 1579108google scholar: lookup
  18. Cullinane A, Elton D, Mumford J. Equine influenza - surveillance and control.. Influenza Other Respir Viruses 2010 Nov;4(6):339-44.
    doi: 10.1111/j.1750-2659.2010.00176.xpmc: PMC4634605pubmed: 20958927google scholar: lookup
  19. Mumford J, Bryant N. The Equine Influenza Expert Surveillance Panel. AHT/BEVA/DEFRA Equine Q. Dis. Surveill. Rep. 2009;5:9–11.
  20. Burrows R, Denyer M. Antigenic properties of some equine influenza viruses.. Arch Virol 1982;73(1):15-24.
    doi: 10.1007/BF01341723pubmed: 6181759google scholar: lookup
  21. Horspool LJ, King A. Equine influenza vaccines in Europe: a view from the animal health industry.. Equine Vet J 2013 Nov;45(6):774-5.
    doi: 10.1111/evj.12171pubmed: 24117938google scholar: lookup
  22. Poetri ON, Bouma A, Murtini S, Claassen I, Koch G, Soejoedono RD, Stegeman JA, van Boven M. An inactivated H5N2 vaccine reduces transmission of highly pathogenic H5N1 avian influenza virus among native chickens.. Vaccine 2009 May 11;27(21):2864-9.
    doi: 10.1016/j.vaccine.2009.02.085pubmed: 19428896google scholar: lookup
  23. Swayne DE, Lee CW, Spackman E. Inactivated North American and European H5N2 avian influenza virus vaccines protect chickens from Asian H5N1 high pathogenicity avian influenza virus.. Avian Pathol 2006 Apr;35(2):141-6.
    doi: 10.1080/03079450600597956pubmed: 16595307google scholar: lookup
  24. The European Medicines Agency (EMA). Guideline on Data Requirements for Changes to the Strain Composition of Authorised Equine Influenza Vaccines in Line with Oie Recommendations. EMA/CVMP/IWP/97961/2013. [(accessed on 1 August 2019)]; Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-data-requirements-changes-strain-composition-authorised-equine-influenza-vaccines-line_en.pdf.
  25. Paillot R, Rash NL, Garrett D, Prowse-Davis L, Montesso F, Cullinane A, Lemaitre L, Thibault JC, Wittreck S, Dancer A. How to Meet the Last OIE Expert Surveillance Panel Recommendations on Equine Influenza (EI) Vaccine Composition: A Review of the Process Required for the Recombinant Canarypox-Based EI Vaccine.. Pathogens 2016 Nov 25;5(4).
    doi: 10.3390/pathogens5040064pmc: PMC5198164pubmed: 27897990google scholar: lookup
  26. . Equine influenza vaccine (inactivated) monograph 0249. European Pharmacopoeia. 9th ed. Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM); Strasbourg, France: 2017. pp. 1051–1053.
  27. Paillot R, Grimmett H, Elton D, Daly JM. Protection, systemic IFNgamma, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host.. Vet Res 2008 May-Jun;39(3):21.
    doi: 10.1051/vetres:2007062pubmed: 18252187google scholar: lookup
  28. The World Organisation for Animal Health (OIE). Equine Influenza: Chapter 3.5.7. [(accessed on 1 August 2019)]; Available online: http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/3.05.07_EQ_INF.pdf.
  29. Gildea S, Arkins S, Cullinane A. A comparative antibody study of the potential susceptibility of Thoroughbred and non-Thoroughbred horse populations in Ireland to equine influenza virus.. Influenza Other Respir Viruses 2010 Nov;4(6):363-72.
    doi: 10.1111/j.1750-2659.2010.00163.xpmc: PMC4634612pubmed: 20958930google scholar: lookup
  30. Cullinane A, Gildea S, Weldon E. Comparison of primary vaccination regimes for equine influenza: working towards an evidence-based regime.. Equine Vet J 2014 Nov;46(6):669-73.
    doi: 10.1111/evj.12214pubmed: 24237177google scholar: lookup
  31. Pouwels HG, Van de Zande SM, Horspool LJ, Hoeijmakers MJ. Efficacy of a non-updated, Matrix-C-based equine influenza subunit-tetanus vaccine following Florida sublineage clade 2 challenge.. Vet Rec 2014 Jun 21;174(25):633.
    doi: 10.1136/vr.101993pmc: PMC4078751pubmed: 24795071google scholar: lookup
  32. Gildea S, Garvey M, Lyons P, Lyons R, Gahan J, Walsh C, Cullinane A. Multifocal Equine Influenza Outbreak with Vaccination Breakdown in Thoroughbred Racehorses.. Pathogens 2018 Apr 17;7(2).
    doi: 10.3390/pathogens7020043pmc: PMC6027538pubmed: 29673169google scholar: lookup
  33. Martella V, Elia G, Decaro N, Di Trani L, Lorusso E, Campolo M, Desario C, Parisi A, Cavaliere N, Buonavoglia C. An outbreak of equine influenza virus in vaccinated horses in Italy is due to an H3N8 strain closely related to recent North American representatives of the Florida sub-lineage.. Vet Microbiol 2007 Mar 31;121(1-2):56-63.
    doi: 10.1016/j.vetmic.2006.11.017pubmed: 17197135google scholar: lookup
  34. Newton JR, Daly JM, Spencer L, Mumford JA. Description of the outbreak of equine influenza (H3N8) in the United Kingdom in 2003, during which recently vaccinated horses in Newmarket developed respiratory disease.. Vet Rec 2006 Feb 11;158(6):185-92.
    doi: 10.1136/vr.158.6.185pubmed: 16474051google scholar: lookup
  35. Barbic L, Madic J, Turk N, Daly J. Vaccine failure caused an outbreak of equine influenza in Croatia.. Vet Microbiol 2009 Jan 1;133(1-2):164-71.
    doi: 10.1016/j.vetmic.2008.06.009pubmed: 18632226google scholar: lookup
  36. Kinsley R, Scott SD, Daly JM. Controlling equine influenza: Traditional to next generation serological assays.. Vet Microbiol 2016 May 1;187:15-20.
    doi: 10.1016/j.vetmic.2016.03.006pubmed: 27066704google scholar: lookup
  37. Yamanaka T, Nemoto M, Bannai H, Tsujimura K, Matsumura T, Kokado H, Gildea S, Cullinane A. Neutralization antibody response to booster/priming immunization with new equine influenza vaccine in Japan.. J Vet Med Sci 2018 Mar 2;80(2):382-386.
    doi: 10.1292/jvms.17-0538pmc: PMC5836781pubmed: 29237998google scholar: lookup
  38. Morley PS, Hanson LK, Bogdan JR, Townsend HG, Appleton JA, Haines DM. The relationship between single radial hemolysis, hemagglutination inhibition, and virus neutralization assays used to detect antibodies specific for equine influenza viruses.. Vet Microbiol 1995 Jun;45(1):81-92.
    doi: 10.1016/0378-1135(94)00105-6pubmed: 7653031google scholar: lookup
  39. Haaheim LR, Schild GC. Antibodies to the strain-specific and cross-reactive determinants of the haemagglutinin of influenza H3N2 viruses. Antiviral activities of the antibodies in biological systems.. Acta Pathol Microbiol Scand B 1980 Dec;88(6):335-40.
    pubmed: 6164247doi: 10.1111/j.1699-0463.1980.tb02652.xgoogle scholar: lookup
  40. Paillot R, Kydd JH, Sindle T, Hannant D, Edlund Toulemonde C, Audonnet JC, Minke JM, Daly JM. Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus.. Vet Immunol Immunopathol 2006 Aug 15;112(3-4):225-33.
    doi: 10.1016/j.vetimm.2006.02.007pubmed: 16621023google scholar: lookup
  41. Geeraedts F, Bungener L, Pool J, ter Veer W, Wilschut J, Huckriede A. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs.. Influenza Other Respir Viruses 2008 Mar;2(2):41-51.
    doi: 10.1111/j.1750-2659.2008.00038.xpmc: PMC4941893pubmed: 19453471google scholar: lookup
  42. Stoel M, Pool J, de Vries-Idema J, Zaaraoui-Boutahar F, Bijl M, Andeweg AC, Wilschut J, Huckriede A. Innate responses induced by whole inactivated virus or subunit influenza vaccines in cultured dendritic cells correlate with immune responses in vivo.. PLoS One 2015;10(5):e0125228.
    doi: 10.1371/journal.pone.0125228pmc: PMC4416761pubmed: 25933037google scholar: lookup
  43. Budimir N, Huckriede A, Meijerhof T, Boon L, Gostick E, Price DA, Wilschut J, de Haan A. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.. PLoS One 2012;7(1):e30898.
    doi: 10.1371/journal.pone.0030898pmc: PMC3267744pubmed: 22303469google scholar: lookup
  44. Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.. Semin Immunol 2018 Oct;39:14-21.
    doi: 10.1016/j.smim.2018.05.001pubmed: 29801750google scholar: lookup
  45. Olafsdottir T, Lindqvist M, Harandi AM. Molecular signatures of vaccine adjuvants.. Vaccine 2015 Sep 29;33(40):5302-7.
    doi: 10.1016/j.vaccine.2015.04.099pubmed: 25989447google scholar: lookup

Citations

This article has been cited 9 times.
  1. Carnet F, Perrin-Cocon L, Paillot R, Lotteau V, Pronost S, Vidalain PO. An inventory of adjuvants used for vaccination in horses: the past, the present and the future. Vet Res 2023 Mar 2;54(1):18.
    doi: 10.1186/s13567-023-01151-3pubmed: 36864517google scholar: lookup
  2. Carnet F, Paillot R, Fortier C, Hue ES, Briot L, de Geoffroy F, Vidalain PO, Pronost S. Immunostimulating Effect of Inactivated Parapoxvirus Ovis on the Serological Response to Equine Influenza Booster Vaccination. Vaccines (Basel) 2022 Dec 14;10(12).
    doi: 10.3390/vaccines10122139pubmed: 36560549google scholar: lookup
  3. Gonzalez-Obando J, Forero JE, Zuluaga-Cabrera AM, Ruiz-Saenz J. Equine Influenza Virus: An Old Known Enemy in the Americas. Vaccines (Basel) 2022 Oct 14;10(10).
    doi: 10.3390/vaccines10101718pubmed: 36298583google scholar: lookup
  4. Lee DH, Lee EB, Seo JP, Ko EJ. Evaluation of concurrent vaccinations with recombinant canarypox equine influenza virus and inactivated equine herpesvirus vaccines. J Anim Sci Technol 2022 May;64(3):588-598.
    doi: 10.5187/jast.2022.e30pubmed: 35709134google scholar: lookup
  5. Pavulraj S, Bergmann T, Trombetta CM, Marchi S, Montomoli E, Alami SSE, Ragni-Alunni R, Osterrieder N, Azab W. Immunogenicity of Calvenza-03 EIV/EHV(®) Vaccine in Horses: Comparative In Vivo Study. Vaccines (Basel) 2021 Feb 17;9(2).
    doi: 10.3390/vaccines9020166pubmed: 33671378google scholar: lookup
  6. Reemers S, van Bommel S, Cao Q, Sutton D, van de Zande S. Protection against the New Equine Influenza Virus Florida Clade I Outbreak Strain Provided by a Whole Inactivated Virus Vaccine. Vaccines (Basel) 2020 Dec 21;8(4).
    doi: 10.3390/vaccines8040784pubmed: 33371484google scholar: lookup
  7. Rask E, Righetti F, Ruiz A, Bjerketorp J, Frosth S, Frykberg L, Jacobsson K, Guss B, Flock JI, Henriques-Normark B, Hartman E, Gustafsson A, Paillot R, Waller AS. Closing the Stable Door on Strangles: Serological Responses of Vaccinated Horses on a Farm Following the Arrival of a New Horse. Animals (Basel) 2025 Dec 13;15(24).
    doi: 10.3390/ani15243584pubmed: 41463869google scholar: lookup
  8. Gonzalez-Obando J, Jaimes-Dueñez J, Zuluaga-Cabrera A, Forero JE, Diaz A, Rojas-Arbeláez C, Ruiz-Saenz J. Seroprevalence of Equine Influenza Virus Antibodies in Horses from Four Localities in Colombia. Viruses 2025 Jul 16;17(7).
    doi: 10.3390/v17070999pubmed: 40733615google scholar: lookup
  9. Elliott S, Olufemi OT, Daly JM. Systematic Review of Equine Influenza A Virus Vaccine Studies and Meta-Analysis of Vaccine Efficacy. Viruses 2023 Nov 28;15(12).
    doi: 10.3390/v15122337pubmed: 38140577google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.